Prize awarded to the Tremtex team from Johns Hopkins University for the Rehabilitation Technology Most Likely to be Commercialized.
Tremtex is working in conjunction with clinical and research partners at the Johns Hopkins School of Medicine to develop an intervention to help Parkinson’s disease patients manage their debilitating motor symptoms. Parkinson’s disease is an incurable, neurodegenerative disorder that affects over 1 million people in the United States and 7 million people worldwide. The standard of care for Parkinson’s disease is medication; however, the effectiveness of medication wanes as the disease progresses. Another option for patients in advanced stages of the disease is deep brain stimulation, an expensive and invasive surgical procedure with strict eligibility criteria. This leaves a significant number of patients without an effective intervention. Tremtex is addressing this gap by providing a low-risk solution for patients whose symptoms are under-managed with existing interventions. The team has designed, STIMband, a non-invasive electrical stimulation device, which delivers low and safe doses of transcranial direct current stimulation (tDCS), to the motor cortices of the brain. The result is the reduction of motor symptoms, including tremors, and improved mobility. STIMband has been designed to ensure patient safety and usability, allowing patients to receive treatment within the comfort of their homes.
Comments are closed.